194 related articles for article (PubMed ID: 35928634)
1. Myeloid-Derived Suppressor Cells and CD68
Lv M; Zhuang X; Shao S; Li X; Cheng Y; Wu D; Wang X; Qiao T
J Immunol Res; 2022; 2022():3621496. PubMed ID: 35928634
[TBL] [Abstract][Full Text] [Related]
2. Distinct alterations of CD68
Shao X; Wu B; Cheng L; Li F; Zhan Y; Liu C; Ji L; Min Z; Ke Y; Sun L; Chen H; Cheng Y
J Transl Med; 2018 Mar; 16(1):48. PubMed ID: 29499727
[TBL] [Abstract][Full Text] [Related]
3. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.
Medrek C; Pontén F; Jirström K; Leandersson K
BMC Cancer; 2012 Jul; 12():306. PubMed ID: 22824040
[TBL] [Abstract][Full Text] [Related]
4. Spatial interaction and functional status of CD68
Liu X; Zhang Z; Yuan J; Yu J; Chen D
Front Immunol; 2024; 15():1396719. PubMed ID: 38799432
[TBL] [Abstract][Full Text] [Related]
5. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
6. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer.
Jackute J; Zemaitis M; Pranys D; Sitkauskiene B; Miliauskas S; Vaitkiene S; Sakalauskas R
BMC Immunol; 2018 Jan; 19(1):3. PubMed ID: 29361917
[TBL] [Abstract][Full Text] [Related]
7. Antibody combinations for optimized staining of macrophages in human lung tumours.
Frafjord A; Skarshaug R; Hammarström C; Stankovic B; Dorg LT; Aamodt H; Woldbaek PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
Scand J Immunol; 2020 Jul; 92(1):e12889. PubMed ID: 32299134
[TBL] [Abstract][Full Text] [Related]
8. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer.
Lan C; Huang X; Lin S; Huang H; Cai Q; Wan T; Lu J; Liu J
Technol Cancer Res Treat; 2013 Jun; 12(3):259-67. PubMed ID: 23289476
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.
Rakaee M; Busund LR; Jamaly S; Paulsen EE; Richardsen E; Andersen S; Al-Saad S; Bremnes RM; Donnem T; Kilvaer TK
Neoplasia; 2019 Mar; 21(3):282-293. PubMed ID: 30743162
[TBL] [Abstract][Full Text] [Related]
10. Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Wen T; Su C; Cheng X; Wang Y; Ma T; Bai Z; Zhang H; Liu Z
Clin Transl Oncol; 2022 Jun; 24(6):1184-1194. PubMed ID: 34988921
[TBL] [Abstract][Full Text] [Related]
11. The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC.
Ohri CM; Shikotra A; Green RH; Waller DA; Bradding P
PLoS One; 2011; 6(7):e21874. PubMed ID: 21799753
[TBL] [Abstract][Full Text] [Related]
12. Detection of M2-macrophages in uveal melanoma and relation with survival.
Bronkhorst IH; Ly LV; Jordanova ES; Vrolijk J; Versluis M; Luyten GP; Jager MJ
Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):643-50. PubMed ID: 20811059
[TBL] [Abstract][Full Text] [Related]
13. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
[TBL] [Abstract][Full Text] [Related]
14. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
15. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity.
Vidyarthi A; Agnihotri T; Khan N; Singh S; Tewari MK; Radotra BD; Chatterjee D; Agrewala JN
Cancer Immunol Immunother; 2019 Dec; 68(12):1995-2004. PubMed ID: 31690954
[TBL] [Abstract][Full Text] [Related]
16. Increased circulating M2-like monocytes in patients with breast cancer.
Zhang B; Cao M; He Y; Liu Y; Zhang G; Yang C; Du Y; Xu J; Hu J; Gao F
Tumour Biol; 2017 Jun; 39(6):1010428317711571. PubMed ID: 28639912
[TBL] [Abstract][Full Text] [Related]
17. Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer.
Pogoda K; Pyszniak M; Rybojad P; Tabarkiewicz J
Oncol Lett; 2016 Dec; 12(6):4785-4794. PubMed ID: 28101225
[TBL] [Abstract][Full Text] [Related]
18. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time.
Ma J; Liu L; Che G; Yu N; Dai F; You Z
BMC Cancer; 2010 Mar; 10():112. PubMed ID: 20338029
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CD68
Troiano G; Caponio VCA; Adipietro I; Tepedino M; Santoro R; Laino L; Lo Russo L; Cirillo N; Lo Muzio L
Oral Oncol; 2019 Jun; 93():66-75. PubMed ID: 31109698
[TBL] [Abstract][Full Text] [Related]
20. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma.
Kong LQ; Zhu XD; Xu HX; Zhang JB; Lu L; Wang WQ; Zhang QB; Wu WZ; Wang L; Fan J; Tang ZY; Sun HC
PLoS One; 2013; 8(3):e59771. PubMed ID: 23555776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
